WO1999009416A3 - Procede de selection de medicaments - Google Patents

Procede de selection de medicaments Download PDF

Info

Publication number
WO1999009416A3
WO1999009416A3 PCT/GB1998/002504 GB9802504W WO9909416A3 WO 1999009416 A3 WO1999009416 A3 WO 1999009416A3 GB 9802504 W GB9802504 W GB 9802504W WO 9909416 A3 WO9909416 A3 WO 9909416A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligopeptide
construction
amino acids
components
oligopeptides
Prior art date
Application number
PCT/GB1998/002504
Other languages
English (en)
Other versions
WO1999009416A2 (fr
Inventor
Henry R Wolfe
Original Assignee
Nycomed Imaging As
Cockbain Julian
Henry R Wolfe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As, Cockbain Julian, Henry R Wolfe filed Critical Nycomed Imaging As
Priority to EP98939765A priority Critical patent/EP1005655A2/fr
Priority to CA002300903A priority patent/CA2300903A1/fr
Priority to JP2000510029A priority patent/JP2001516029A/ja
Priority to AU88168/98A priority patent/AU8816898A/en
Publication of WO1999009416A2 publication Critical patent/WO1999009416A2/fr
Publication of WO1999009416A3 publication Critical patent/WO1999009416A3/fr
Priority to NO20000811A priority patent/NO20000811L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un procédé de sélection d'un composé médicamenteux candidat consistant: (i) à identifier un oligopeptide de départ présentant une affinité de liaison avec la surface d'une cellule ou un autre site récepteur; (ii) à générer plusieurs oligopeptides homologues présentant par rapport audit oligopeptide de départ des modifications en un seul site de l'acide aminé; (iii) à identifier des éléments desdits oligopeptides de départ responsables de leur structure secondaire; (iv) pour les sites de modification identifiés en (ii), à sélectionner un ensemble d'acides aminés; (v) pour les composants identifiés en (iii), à sélectionner au moins un acide aminé non naturel qui imite la structure secondaire du composant; (vi) à générer une première bibliothèque combinatoire d'oligopeptides présentant au moins les résidus d'acides aminés des sites de modifications identifiés correspondant aux susdits ensembles sélectionnés d'acides aminés; (vii) à identifier les éléments de la première bibliothèque présentant une activité de liaison supérieure à un minimum prédéterminé et générer une autre bibliothèque combinatoire d'oligopeptides comportant des éléments non présents dans ladite première bibliothèque, et à identifier les éléments de cette autre bibliothèque ayant des taux d'affinité accrus par rapport aux éléments identifiés de la première bibliothèque, sous réserve que l'une au moins de la première et des autres bibliothèques contienne des oligopeptides renfermant des résidus desdits acides ou acides aminés non naturels; et (viii) à sélectionner un médicament candidat parmi les éléments identifiés de la ou des bibliothèques.
PCT/GB1998/002504 1997-08-20 1998-08-20 Procede de selection de medicaments WO1999009416A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP98939765A EP1005655A2 (fr) 1997-08-20 1998-08-20 Procede de selection de medicaments
CA002300903A CA2300903A1 (fr) 1997-08-20 1998-08-20 Procede de selection de medicaments
JP2000510029A JP2001516029A (ja) 1997-08-20 1998-08-20 薬物の選択方法
AU88168/98A AU8816898A (en) 1997-08-20 1998-08-20 Method of drug selection
NO20000811A NO20000811L (no) 1997-08-20 2000-02-18 FremgangsmÕte for valg av medikament

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5685997P 1997-08-20 1997-08-20
GBGB9717652.3A GB9717652D0 (en) 1997-08-20 1997-08-20 Method
GB9717652.3 1997-08-20

Publications (2)

Publication Number Publication Date
WO1999009416A2 WO1999009416A2 (fr) 1999-02-25
WO1999009416A3 true WO1999009416A3 (fr) 1999-10-21

Family

ID=10817781

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1998/002504 WO1999009416A2 (fr) 1997-08-20 1998-08-20 Procede de selection de medicaments
PCT/GB1998/002510 WO1999009417A2 (fr) 1997-08-20 1998-08-20 Procede de selection de medicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002510 WO1999009417A2 (fr) 1997-08-20 1998-08-20 Procede de selection de medicaments

Country Status (7)

Country Link
EP (1) EP1005655A2 (fr)
JP (1) JP2001516029A (fr)
AU (2) AU8816898A (fr)
CA (1) CA2300903A1 (fr)
GB (1) GB9717652D0 (fr)
NO (1) NO20000811L (fr)
WO (2) WO1999009416A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809776D0 (en) 1998-05-07 1998-07-08 Nycomed Imaging As Method
GB9809782D0 (en) * 1998-05-07 1998-07-08 Nycomed Imaging As Method
GB9809780D0 (en) * 1998-05-07 1998-07-08 Nycomed Imaging As Method
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
CA2707840A1 (fr) 2007-08-20 2009-02-26 Allozyne, Inc. Molecules substituees par des acides amines
PL2958935T3 (pl) 2013-02-20 2020-03-31 Bergen Teknologioverføring As Szczepionka
WO2020039387A1 (fr) * 2018-08-24 2020-02-27 Vestlandets Innovasjonsselskap As (Vis) Mutants d'entérotoxines stables à la chaleur utiles en tant qu'antigènes de vaccin antidiarrhéique

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267802A2 (fr) * 1986-11-14 1988-05-18 Genetic Systems Corporation Antigène synthétique pour la détection de maladie de SIDA et maladies s'y rapportant
US4965343A (en) * 1988-01-28 1990-10-23 Hoffmann-La Roche Inc. Method of peptide synthesis
EP0418617A1 (fr) * 1989-08-31 1991-03-27 Mitsubishi Petrochemical Co., Ltd. Procédé de préparation d'ostéocalcine humaine
EP0529075A1 (fr) * 1990-04-09 1993-03-03 Asahi Glass Company Ltd. Calcitonine hybride
US5432018A (en) * 1990-06-20 1995-07-11 Affymax Technologies N.V. Peptide library and screening systems
WO1996040186A1 (fr) * 1995-06-07 1996-12-19 Connective Therapeutics, Inc. Facteur similaire a la relaxine, ses procedes et emplois
WO1997000267A1 (fr) * 1995-06-16 1997-01-03 Pence Composition de banques combinatoires a limitation conformationnelle et procedes d'utilisation
WO1997022617A1 (fr) * 1995-12-18 1997-06-26 Praecis Pharmaceuticals Incorporated Procedes d'identification de composes se liant a une cible

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267802A2 (fr) * 1986-11-14 1988-05-18 Genetic Systems Corporation Antigène synthétique pour la détection de maladie de SIDA et maladies s'y rapportant
US4965343A (en) * 1988-01-28 1990-10-23 Hoffmann-La Roche Inc. Method of peptide synthesis
EP0418617A1 (fr) * 1989-08-31 1991-03-27 Mitsubishi Petrochemical Co., Ltd. Procédé de préparation d'ostéocalcine humaine
EP0529075A1 (fr) * 1990-04-09 1993-03-03 Asahi Glass Company Ltd. Calcitonine hybride
US5432018A (en) * 1990-06-20 1995-07-11 Affymax Technologies N.V. Peptide library and screening systems
WO1996040186A1 (fr) * 1995-06-07 1996-12-19 Connective Therapeutics, Inc. Facteur similaire a la relaxine, ses procedes et emplois
WO1997000267A1 (fr) * 1995-06-16 1997-01-03 Pence Composition de banques combinatoires a limitation conformationnelle et procedes d'utilisation
WO1997022617A1 (fr) * 1995-12-18 1997-06-26 Praecis Pharmaceuticals Incorporated Procedes d'identification de composes se liant a une cible

Also Published As

Publication number Publication date
WO1999009417A2 (fr) 1999-02-25
GB9717652D0 (en) 1997-10-22
CA2300903A1 (fr) 1999-02-25
NO20000811L (no) 2000-04-12
WO1999009417A9 (fr) 1999-05-27
AU8817398A (en) 1999-03-08
WO1999009416A2 (fr) 1999-02-25
NO20000811D0 (no) 2000-02-18
EP1005655A2 (fr) 2000-06-07
WO1999009417A3 (fr) 1999-08-12
JP2001516029A (ja) 2001-09-25
AU8816898A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
Moran et al. Radio frequency tag encoded combinatorial library method for the discovery of tripeptide-substituted cinnamic acid inhibitors of the protein tyrosine phosphatase PTP1B
Flood et al. DNA encoded libraries: a visitor's guide
US20070269858A1 (en) Combinatorial Biology
PT1242821E (pt) Método de rastreio directo
WO2001075767A3 (fr) Selection de sites de recombinaison par enjambement in silico
ATE234268T1 (de) Synthese von n-substituierten oligomeren
EP0801307A3 (fr) Composition et procédé pour criblage de banques de substances pharmaceutiques
WO2001094946A3 (fr) Microreseaux permettant de realiser des analyses proteomiques
IL199259A0 (en) Artificial receptors, building blocks, and methods
PT839152E (pt) Bibliotecas combinatorias de compostos bioquimicos marcados e metodos para as produzir.
Frank High-density synthetic peptide microarrays: emerging tools for functional genomics and proteomics
WO1999009416A3 (fr) Procede de selection de medicaments
CA2302147A1 (fr) Procedes d'analyse de proteines
ATE141611T1 (de) Schnellsynthese und screening von peptidmimetika
DK0868427T3 (da) Fremgangsmåder til at idenficere forbindelser, der binder til et mål
WO2000031246A3 (fr) Methodes de preparation de banques d'acides nucleiques et de polypeptides et utilisations de telles banques
EP1310790A3 (fr) Système de détection de l'affinité par colonnes multiples
WO2002095393A3 (fr) Evolution des medicaments : conception rationnelle des medicaments aux « points chauds »
EP0845529A3 (fr) Récepteur humain couplé à la protéine G, cloné à partir d'une banque d'ADN complémentaire de cerveau foetal
DE60036794D1 (de) Proteomabbau
DK0774116T3 (da) Fremgangsmåde til screening af biblioteker af forbindelser
DK1018008T3 (da) Fremgangsmåde til identifikation af förerstrukturer eller aktive forbindelser
DK1123396T3 (da) Minimale promotorer og anvendelser deraf
Seneci Encoding techniques for pool libraries of small organic molecules
WO2003012721A3 (fr) Modeles predictifs lies a l'activite d'une molecule d'interet

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2300903

Country of ref document: CA

Ref country code: CA

Ref document number: 2300903

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09506695

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998939765

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998939765

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998939765

Country of ref document: EP